Dashboard
Discussions
Watchlists
Collections
Tools
More
Events
SIGN UP
SIGN IN
ENTITY
Simcere Pharmaceutical Group (2096 HK)
Watchlist
53
Analysis
Health Care
•
China
Simcere Pharmaceutical Group manufactures and supplies branded generic pharmaceuticals to the China market. The Company's products include antibiotics, anti-cancer medications and anti-stroke medications.
more
Watchlist
All
Insights
Broker
Sponsored
Syndicated
Podcast
Buy side
Refresh
Focused
Suggested
bearish
•
Simcere Pharmaceutical Group
•
13 Sep 2022 08:57
Simcere Pharmaceutical Group (2096.HK) 22H1 - Gloomy Outlook and Risks in Profits
Simcere’s profit was driven by investment business, which will further decline due to unfriendly macro. The pipeline quality is not high, leading...
Xinyao (Criss) Wang
Follow
227 Views
Share
bullish
•
CIMC Vehicle Group Co Ltd
•
26 Jul 2022 10:09
Hong Kong CEO & Director Dealings - 26th July 2022
The data in this insight is collated from the "shareholding disclosure" link on the HKEx website. These insights also flags those companies where...
David Blennerhassett
Follow
311 Views
Share
bearish
•
Thematic (Sector/Industry)
•
24 Apr 2022 09:04
China Healthcare Weekly (Apr.22) - TCM VBP Results, R&D Thinking Mode, Biotech Delisting
Guangdong Alliance released the VBP results of TCM; The ability to identify innovation and the thinking mode is more important for Pharma; There...
Xinyao (Criss) Wang
Follow
298 Views
Share
bearish
•
Simcere Pharmaceutical Group
•
11 Apr 2022 00:26
Simcere Pharmaceutical (2096 HK): Double-Digit Topline Growth; Margin Deteriorating Spoils the Party
Despite increasing contribution of innovative products, Simcere’s profitability is under pressure, reflecting pricing headwind. Elevated R&D and...
Tina Banerjee
Follow
365 Views
Share
bearish
•
Thematic (Sector/Industry)
•
10 Feb 2022 09:05
Would the Cheap Versions of Oral COVID-19 Antiviral Bring New Opportunities for Chinese Companies?
Some Chinese companies are allowed to make cheap versions of Merck’s molnupiravir based on the MPP agreement.We analyzed the impact and outlook,...
Xinyao (Criss) Wang
Follow
216 Views
Share
First
Previous
3
4
5
6
7
8
9
Next
Last
Copyright © 2022 Smartkarma Innovations Pte Ltd. All Rights Reserved. v3.33.1
x